Jens Klotsche1, Anna Raab1, Martina Niewerth2, Claudia Sengler2, Gerd Ganser3, Tilmann Kallinich4, Tim Niehues5, Markus Hufnagel6, Angelika Thon7, Toni Hospach8, Gerd Horneff9, Kirsten Minden1. 1. German Rheumatism Research Centre Berlin and Charité University Hospital Berlin, Berlin, Germany. 2. German Rheumatism Research Centre Berlin, Berlin, Germany. 3. St. Josef-Stift Sendenhorst Hospital, Sendenhorst, Germany. 4. Charité University Hospital Berlin, Berlin, Germany. 5. HELIOS Klinikum Krefeld, Krefeld, Germany. 6. University Medical Center Freiburg, Freiburg, Germany. 7. Hannover Medical School, Hannover, Germany. 8. Olgahospital, Clinical Center Stuttgart, Stuttgart, Germany. 9. Asklepios Clinic Sankt Augustin, St. Augustin, Germany.
Abstract
OBJECTIVE: To investigate the clinical presentation and medical treatment of patients with systemic juvenile idiopathic arthritis (JIA) during the first year of illness. Our study focused on 3-year outcomes in a subsample of patients who were followed up longitudinally. METHODS: From 2000 to 2013, 597 patients with systemic JIA and a disease duration of ≤12 months were recorded in the National Pediatric Rheumatologic Database. Among those patients, 3-year outcome data were available for 133. These data included the clinical Juvenile Arthritis Disease Activity Score in 10 joints (JADAS-10) and the physician's global assessment score (on a numerical rating scale), as well as assessment of joint involvement, growth retardation, and patient-reported outcomes. RESULTS: The median clinical JADAS-10 declined significantly, from 7 in 2000 to 2 in 2013, while the proportion of patients with inactive disease increased from 19% in 2000 to 41% in 2013. The rate of treatment with systemic glucocorticoids and disease-modifying antirheumatic drugs (DMARDs) remained stable from 2000 to 2013. By 2013, the proportion of patients with systemic JIA who were treated with biologic DMARDs had increased to 20%. At 3-year follow-up, 72% of patients with systemic JIA had inactive disease, and 77% had no functional limitations. Growth retardation was associated with persistently high disease activity and continuing treatment with systemic glucocorticoids. At the 3-year follow-up, one-third of patients were still being treated with systemic glucocorticoids. CONCLUSION: The proportion of patients with inactive disease has increased over the past decade. Possible explanations may include improved access to specialized care, additional treatment options, and earlier or faster step-up treatment. However, challenges in the management of systemic JIA remain, as ∼30% of patients continue to present with ongoing active disease.
OBJECTIVE: To investigate the clinical presentation and medical treatment of patients with systemic juvenile idiopathic arthritis (JIA) during the first year of illness. Our study focused on 3-year outcomes in a subsample of patients who were followed up longitudinally. METHODS: From 2000 to 2013, 597 patients with systemic JIA and a disease duration of ≤12 months were recorded in the National Pediatric Rheumatologic Database. Among those patients, 3-year outcome data were available for 133. These data included the clinical Juvenile Arthritis Disease Activity Score in 10 joints (JADAS-10) and the physician's global assessment score (on a numerical rating scale), as well as assessment of joint involvement, growth retardation, and patient-reported outcomes. RESULTS: The median clinical JADAS-10 declined significantly, from 7 in 2000 to 2 in 2013, while the proportion of patients with inactive disease increased from 19% in 2000 to 41% in 2013. The rate of treatment with systemic glucocorticoids and disease-modifying antirheumatic drugs (DMARDs) remained stable from 2000 to 2013. By 2013, the proportion of patients with systemic JIA who were treated with biologic DMARDs had increased to 20%. At 3-year follow-up, 72% of patients with systemic JIA had inactive disease, and 77% had no functional limitations. Growth retardation was associated with persistently high disease activity and continuing treatment with systemic glucocorticoids. At the 3-year follow-up, one-third of patients were still being treated with systemic glucocorticoids. CONCLUSION: The proportion of patients with inactive disease has increased over the past decade. Possible explanations may include improved access to specialized care, additional treatment options, and earlier or faster step-up treatment. However, challenges in the management of systemic JIA remain, as ∼30% of patients continue to present with ongoing active disease.
Authors: Yukiko Kimura; Sriharsha Grevich; Timothy Beukelman; Esi Morgan; Peter A Nigrovic; Kelly Mieszkalski; T Brent Graham; Maria Ibarra; Norman Ilowite; Marisa Klein-Gitelman; Karen Onel; Sampath Prahalad; Marilynn Punaro; Sarah Ringold; Dana Toib; Heather Van Mater; Jennifer E Weiss; Pamela F Weiss; Laura E Schanberg Journal: Pediatr Rheumatol Online J Date: 2017-04-11 Impact factor: 3.054
Authors: M Bielak; E Husmann; N Weyandt; J-P Haas; B Hügle; G Horneff; U Neudorf; T Lutz; E Lilienthal; T Kallinich; K Tenbrock; R Berendes; T Niehues; H Wittkowski; E Weißbarth-Riedel; G Heubner; P Oommen; J Klotsche; Dirk Foell; E Lainka Journal: Pediatr Rheumatol Online J Date: 2018-04-05 Impact factor: 3.054
Authors: Gail H Deutsch; R Paul Guillerman; Johannes Birgmeier; Karthik Jagadeesh; Scott Canna; Grant Schulert; Vivian E Saper; Guangbo Chen; Robin Deterding; Jianpeng Xu; Ann N Leung; Layla Bouzoubaa; Khalid Abulaban; Kevin Baszis; Edward M Behrens; James Birmingham; Alicia Casey; Michal Cidon; Randy Q Cron; Aliva De; Fabrizio De Benedetti; Ian Ferguson; Martha P Fishman; Steven I Goodman; T Brent Graham; Alexei A Grom; Kathleen Haines; Melissa Hazen; Lauren A Henderson; Assunta Ho; Maria Ibarra; Christi J Inman; Rita Jerath; Khulood Khawaja; Daniel J Kingsbury; Marisa Klein-Gitelman; Khanh Lai; Sivia Lapidus; Clara Lin; Jenny Lin; Deborah R Liptzin; Diana Milojevic; Joy Mombourquette; Karen Onel; Seza Ozen; Maria Perez; Kathryn Phillippi; Sampath Prahalad; Suhas Radhakrishna; Adam Reinhardt; Mona Riskalla; Natalie Rosenwasser; Johannes Roth; Rayfel Schneider; Dieneke Schonenberg-Meinema; Susan Shenoi; Judith A Smith; Hafize Emine Sönmez; Matthew L Stoll; Christopher Towe; Sara O Vargas; Richard K Vehe; Lisa R Young; Jacqueline Yang; Tushar Desai; Raymond Balise; Ying Lu; Lu Tian; Gill Bejerano; Mark M Davis; Purvesh Khatri; Elizabeth D Mellins Journal: Ann Rheum Dis Date: 2019-09-27 Impact factor: 19.103
Authors: Justine Maller; Emily Fox; K T Park; Sarah Sertial Paul; Kevin Baszis; Charlotte Borocco; Sampath Prahalad; Pierre Quartier; Adam Reinhardt; Dieneke Schonenberg-Meinema; Lauren Shipman-Duensing; Maria Teresa Terreri; Julia Simard; Idit Lavi; Elizabeth Chalom; Joyce Hsu; Devy Zisman; Elizabeth D Mellins Journal: J Rheumatol Date: 2020-06-15 Impact factor: 4.666
Authors: Rosemary G Peterson; Rui Xiao; Karen E James; Hannah Katcoff; Brian T Fisher; Pamela F Weiss Journal: Arthritis Care Res (Hoboken) Date: 2021-10-07 Impact factor: 4.794